PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.43 - 1.45
1.18 - 2.36
880.0K / 1.73M (Avg.)
-18.00 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.32%
Negative revenue growth while 1177.HK stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.39%
Negative gross profit growth while 1177.HK is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-399.43%
Negative EBIT growth while 1177.HK is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-4.34%
Negative operating income growth while 1177.HK is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-714.16%
Negative net income growth while 1177.HK stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-713.16%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-713.16%
Negative diluted EPS growth while 1177.HK is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.00%
Share change of 0.00% while 1177.HK is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.24%
Negative OCF growth while 1177.HK is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
45.21%
FCF growth of 45.21% while 1177.HK is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
178562.95%
10Y revenue/share CAGR above 1.5x 1177.HK's 39.24%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
178.11%
Positive 5Y CAGR while 1177.HK is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
28.80%
Positive 3Y CAGR while 1177.HK is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
366.34%
10Y OCF/share CAGR above 1.5x 1177.HK's 41.71%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
321.78%
Positive OCF/share growth while 1177.HK is negative. John Neff might see a comparative advantage in operational cash viability.
216.09%
3Y OCF/share CAGR of 216.09% while 1177.HK is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
79.08%
Below 50% of 1177.HK's 165.55%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
83.79%
5Y net income/share CAGR above 1.5x 1177.HK's 23.08%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-129.55%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-35.33%
Negative equity/share CAGR over 10 years while 1177.HK stands at 199.44%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
23.77%
Positive 5Y equity/share CAGR while 1177.HK is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-0.97%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.18%
Inventory is declining while 1177.HK stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.13%
Asset growth of 0.13% while 1177.HK is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
-0.66%
We have a declining book value while 1177.HK shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-7.72%
We’re deleveraging while 1177.HK stands at 1.74%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-100.00%
Our R&D shrinks while 1177.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-2.08%
We cut SG&A while 1177.HK invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.